During early development phases, we help you to:

• Conduct early reviews to identify the unmet needs and disease burden and define the patient population. 
• Develop early economic models to explore pricing thresholds, assess early cost-effectiveness, and inform go/no-go decisions for pipeline candidates.
• Validate existing disease-specific patient-reported outcome measures (PROMs), or develop new PROMs if none currently exist.
• Navigate uncertainty with clear, structured and forward-looking evidence strategies tailored to your product’s specific context, incorporating methods like structured expert elicitation.
• Embed considerations of sustainability and equity into your initial evidence plans to align with evolving societal values.

YHEC will help you to:

• Integrate the patient voice and broader real-world perspectives on health equity and inclusion into evidence development by using outcomes research in a meaningful manner.
• Synthesise your evidence and value story through literature reviews, economic models and statistical analysis.
• Create compelling value communications that are easy to interpret and resonate with stakeholders.
• Align internal evidence with the expectations of HTA bodies to avoid costly rework and improve the chances of positive outcomes.
• Identify and address evidentiary challenges in rare, niche or complex indications through expert data synthesis and rigorous statistical analysis.
• Conduct structured expert elicitation where evidence may be limited, incomplete, or uncertain.
• Map utility values collected using disease-specific patient-reported outcome measures (PROMS) to generic PROMs (e.g. EQ-5D).

For successful market access, your health technology assessment (HTA) and reimbursement submissions must be robust and thorough. We provide support to:

• Anticipate payer and decision-maker expectations for models and evidence strategies.
• Adapt global evidence to local HTA requirements, ensuring your submission is relevant and persuasive for specific national or regional contexts.
• Create compelling, aligned and defensible HTA submissions that resonate with stakeholders.
• Prepare for HTA consultations and scientific advice meetings.

After launch, continuous evidence generation is important for long-term success. We help you to:

• Strengthen value propositions with data that reflect the lived experiences of patients.
• Address any new evidentiary challenges that emerge in the real world.
• Prepare for evolving healthcare expectations by embedding considerations of sustainability and ethics into your ongoing evidence plans.
• Analyse patient registries and health databases to collect real-world data supporting your product.
• Leverage real-world evidence to enhance your value messages and communications.